CTAD 2022 Preview: Lecanemab Is Headliner After Gantenerumab’s Failure
Anti-Amyloid Debate Continues With Mixed Readouts
Phase III results for Eisai/Biogen’s lecanemab are the main event at the Clinical Trials on Alzheimer’s Disease meeting, but other data – even Roche’s failed Phase III gantenerumab studies – also may have implications for the amyloid-clearing antibody.
